Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

7.66

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

0.07

EPS Last/This Y

2.15

EPS This/Next Y

0.57

Price

2.55

Target Price

9.38

Analyst Recom

1.25

Performance Q

6.25

Relative Volume

1.62

Beta

0.22

Ticker: LPTX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19LPTX2.780.480.453208
2024-12-20LPTX2.880.450.403274
2024-12-23LPTX2.860.370.452163
2024-12-24LPTX2.910.370.002186
2024-12-26LPTX2.960.320.002459
2024-12-27LPTX2.950.320.002464
2024-12-30LPTX2.920.320.002465
2024-12-31LPTX2.870.310.192491
2025-01-02LPTX3.210.200.122958
2025-01-03LPTX3.330.211.202969
2025-01-06LPTX3.340.251.623154
2025-01-07LPTX3.460.300.013256
2025-01-08LPTX3.370.200.074496
2025-01-09LPTX3.380.200.074496
2025-01-10LPTX3.040.200.024496
2025-01-13LPTX3.10.150.415875
2025-01-14LPTX3.080.140.006065
2025-01-15LPTX3.250.140.016591
2025-01-16LPTX2.590.140.296917
2025-01-17LPTX2.550.121.128038
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19LPTX2.78-91.7- -1.83
2024-12-20LPTX2.89-91.7- -1.83
2024-12-23LPTX2.89-91.7- -1.83
2024-12-24LPTX2.91-91.7- -1.83
2024-12-26LPTX2.98-91.7- -1.83
2024-12-27LPTX2.95-91.7- -1.83
2024-12-30LPTX2.92-91.7- -1.83
2024-12-31LPTX2.88-91.7- -1.83
2025-01-02LPTX3.24-91.7- -1.83
2025-01-03LPTX3.35-91.7- -1.83
2025-01-06LPTX3.34-91.7- -1.83
2025-01-07LPTX3.43-91.7- -1.83
2025-01-08LPTX3.38-91.7- -1.83
2025-01-09LPTX3.38-91.7- -1.83
2025-01-10LPTX3.04-91.7- -1.83
2025-01-13LPTX3.10-91.7- -1.83
2025-01-14LPTX3.08-91.7- -1.83
2025-01-15LPTX3.25-91.7- -1.83
2025-01-16LPTX2.59-91.7- -1.83
2025-01-17LPTX2.55-91.7- -1.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19LPTX0.00-0.124.99
2024-12-20LPTX0.00-0.124.99
2024-12-23LPTX0.00-0.124.99
2024-12-24LPTX0.00-0.124.99
2024-12-26LPTX0.00-0.127.50
2024-12-27LPTX0.00-0.127.50
2024-12-30LPTX0.00-0.127.50
2024-12-31LPTX0.00-0.127.50
2025-01-02LPTX0.00-0.127.50
2025-01-03LPTX0.00-0.127.50
2025-01-06LPTX0.00-0.127.50
2025-01-07LPTX0.00-0.127.50
2025-01-08LPTX0.00-0.127.50
2025-01-09LPTX0.00-0.127.50
2025-01-10LPTX0.00-0.127.50
2025-01-13LPTX0.00-0.127.66
2025-01-14LPTX0.00-0.127.66
2025-01-15LPTX0.00-0.127.66
2025-01-16LPTX0.00-0.127.66
2025-01-17LPTX0.00-0.127.66
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.44

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

Institutional Transactions

-0.12

Beta

0.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

21

Sentiment Score

6

Actual DrawDown %

93.9

Max Drawdown 5-Year %

-96.8

Target Price

9.38

P/E

Forward P/E

PEG

P/S

P/B

1.99

P/Free Cash Flow

EPS

-1.93

Average EPS Est. Cur. Y​

-1.83

EPS Next Y. (Est.)

-1.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.62

Return on Equity vs Sector %

-151.5

Return on Equity vs Industry %

-138.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.06

EBIT Estimation

Leap Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 54
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
stock quote shares LPTX – Leap Therapeutics Inc Stock Price stock today
news today LPTX – Leap Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPTX – Leap Therapeutics Inc yahoo finance google finance
stock history LPTX – Leap Therapeutics Inc invest stock market
stock prices LPTX premarket after hours
ticker LPTX fair value insiders trading